CMS MG-K10 has been approved to conduct clinical trials for new indications

CMS (00867.HK) announced that the group has obtained the approval notice from the National Medical Products Administration of China for the Class 1 new drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection "MG-K10," granting permission for MG-K10 to conduct clinical trials for chronic obstructive pulmonary disease.

MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate to severe atopic dermatitis (AD), meeting the primary research endpoints designed in the study protocol